

Resource Summary Report

Generated by [Kravitz](#) on Sep 10, 2026

Roswell Park Comprehensive Cancer Center

RRID:SCR_004471

Type: Tool

Proper Citation

Roswell Park Comprehensive Cancer Center (RRID:SCR_004471)

Resource Information

URL: <https://www.roswellpark.org/>

Proper Citation: Roswell Park Comprehensive Cancer Center (RRID:SCR_004471)

Description: Cancer research and treatment center located in Buffalo, New York. Founded by surgeon Roswell Park in 1898, the center was the first in the United States to specifically focus on cancer research. The center is usually called Roswell Park in short.

Abbreviations: RPCI

Synonyms: Roswell Park Cancer Institute

Resource Type: institution

Keywords: cancer, research, education

Resource Name: Roswell Park Comprehensive Cancer Center

Resource ID: SCR_004471

Alternate IDs: , Wikidata Q7370121, ISNI 0000 0001 2181 8635, GRID grid.240614.5, nlx_143749, Crossref Funder ID 100001320

Alternate URLs: <https://ror.org/0499dwk57>

Old URLs: <http://www.roswellpark.edu/>

Record Creation Time: 20220129T080224+0000

Record Last Update: 20260905T132520+0000

Ratings and Alerts

No rating or validation information has been found for Roswell Park Comprehensive Cancer Center.

No alerts have been found for Roswell Park Comprehensive Cancer Center.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [Kravitz](#) .

Barrio-Calvo M, et al. (2026) An Exploratory Study of the Impact of a CCL21-Derived C-Terminal Peptide on Dendritic Cell Lymph Node Homing. Journal of immunology research, 2026, 8833079.

La Rosa S, et al. (2026) Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations: The Kidney Cancer Association Scientific Statement. Cancers, 18(9).

Johansson H, et al. (2016) Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast cancer research : BCR, 18(1), 110.

Bielack SS, et al. (2015) Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33(20), 2279.